A double-blind, placebo-controlled, crossover trial of the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Molecular Genetics and Metabolism

• Publication date

  2016-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.ymgme.2016.04.012PMID 27179999
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A clinical trial of safety and tolerability for the selective dopamine D1 receptor antagonist ecopipam in patients with Lesch-Nyhan disease.

  2016influential reference
• Brain white matter volume abnormalities in Lesch-Nyhan disease and its variants

  2015cited by this paper
• A D1 Receptor Antagonist, Ecopipam, for Treatment of Tics in Tourette Syndrome

  2014cited by this paper
• Loss of dopamine phenotype among midbrain neurons in Lesch–Nyhan disease

  2014cited by this paper
• Genotype-phenotype correlations in neurogenetics: Lesch-Nyhan disease as a model disorder.

  2014cited by this paper
• Treatment of motor and behavioural symptoms in three Lesch-Nyhan patients with intrathecal baclofen

  2014cited by this paper
• Treatment of Lesch-Nyhan disease with S-adenosylmethionine: experience with five young Malaysians, including a girl.

  2014cited by this paper
• Consequences of Delayed Dental Extraction in Lesch‐Nyhan Disease

  2014cited by this paper
• Regional brain volume abnormalities in Lesch-Nyhan disease and its variants: a cross-sectional study.

  2013cited by this paper
• A population study of Lesch–Nyhan disease in the UK

  2011cited by this paper
• Genotype-Phenotype Correlations in Lesch-Nyhan Disease

  2011cited by this paper
• Levodopa is not a useful treatment for Lesch‐Nyhan disease

  2011cited by this paper
• Attenuated variants of Lesch-Nyhan disease

  2010cited by this paper
• Levodopa therapy in a Lesch‐Nyhan disease patient: Pathological, biochemical, neuroimaging, and therapeutic remarks

  2008cited by this paper
• Randomized Controlled Trials of the D1/D5 Antagonist Ecopipam for Weight Loss in Obese Subjects

  2007cited by this paper
• Dramatic reduction in self-injury in Lesch–Nyhan disease following S-adenosylmethionine administration

  2006cited by this paper
• The Role of Dopamine Receptors in the Neurobehavioral Syndrome Provoked by Activation of L-Type Calcium Channels in Rodents

  2006cited by this paper
• Delineation of the motor disorder of Lesch-Nyhan disease.

  2006cited by this paper
• The neonate-6-hydroxydopamine-lesioned rat: a model for clinical neuroscience and neurobiological principles.

  2005cited by this paper
• Behavioral aspects of Lesch-Nyhan disease and its variants.

  2005cited by this paper
• Botulinum toxin as a novel treatment for self‐mutilation in Lesch—Nyhan syndrome

  2005cited by this paper
• Behavioral aspects of Lesch–Nyhan disease and its variants

  2005cited by this paper
• Self-Biting Induced by Activation of L-Type Calcium Channels in Mice: Dopaminergic Influences

  2003cited by this paper
• Modes and patterns of self-mutilation in persons with Lesch-Nyhan disease.

  2003cited by this paper
• Self-Biting Induced by Activation of L-Type Calcium Channels in Mice: Serotonergic Influences

  2002cited by this paper
• Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self-administration by humans

  2001cited by this paper
• The Behavior Problems Inventory: An Instrument for the Assessment of Self-Injury, Stereotyped Behavior, and Aggression/Destruction in Individuals with Developmental Disabilities

  2001cited by this paper
• Neurocognitive functioning in Lesch-Nyhan disease and partial hypoxanthine-guanine phosphoribosyltransferase deficiency

  2001cited by this paper
• Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine

  2001cited by this paper
• Self-injurious behavior: gene-brain-behavior relationships.

  2001cited by this paper
• A Review of Behavioral Treatments used for Lesch-Nyhan Syndrome

  2000cited by this paper
• Lesch-Nyhan disease and the basal ganglia.

  2000cited by this paper
• Gabapentin for self-injurious behavior in Lesch-Nyhan syndrome.

  1999cited by this paper
• Case Report: The Effects of Selective Serotonergic Reuptake Inhibitors Combined with Behavioral Treatment on Self-Injury Associated with Lesch-Nyhan Syndrome

  1998cited by this paper
• Carbamazepine Trial for Lesch-Nyhan Self-Mutilation

  1996cited by this paper
• Risperidone antagonism of self-mutilation in a Lesch-Nyhan patient.

  1996cited by this paper
• Evaluation of SCH 39166 as PET ligand for central D1 dopamine receptor binding and occupancy in man

  1995cited by this paper
• Lack of apparent antipsychotic effect of the D1-dopamine recepotr antagonist SCH39166 in acutely ill schizophrenic patients

  1995cited by this paper
• Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia

  1995cited by this paper
• COGNITIVE FUNCTIONING IN LESCH‐NYHAN SYNDROME

  1995cited by this paper
• Treatment of Lesch-Nyhan syndrome with AICAR.

  1994cited by this paper
• Self-injury in Lesch-Nyhan disease

  1994cited by this paper
• Cognitive abilities of patients with Lesch-Nyhan disease

  1992cited by this paper
• Pharmacologic evaluation of SCH-39166, A-69024, NO-0756, and SCH-23390 in neonatal-6-OHDA-lesioned rats. Further evidence that self-mutilatory behavior induced by L-dopa is related to D1 dopamine receptors.

  1992cited by this paper
• Pharmacotherapy for self-injurious behavior: preliminary tests of the D1 hypothesis.

  1990cited by this paper
• A dopamine deficiency model of Lesch-Nyhan disease--the neonatal-6-OHDA-lesioned rat.

  1990cited by this paper
• Pharmacotherapy for self-injurious behavior: preliminary tests of the D1 hypothesis.

  1989cited by this paper
• Dopamine deficiency in self-injurious behavior.

  1989cited by this paper
• Lesch‐nyhan syndrome: A study of motor behavior and cerebrospinal fluid neurotransmitters

  1988cited by this paper
• Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.

  1988cited by this paper
• Hypoxanthine and tetrahydrobiopterin treatment of a patient with features of the Lesch-Nyhan syndrome.

  1986cited by this paper
• HYPOXANTHINE AND TETRAHYDROBIOPTERIN TREATMENT OF A PATIENT WITH FEATURES OF THE LESCH-NYHAN SYNDROME: 118

  1985cited by this paper
• Neonatal-6-hydroxydopamine treatment: model of susceptibility for self-mutilation in the Lesch-Nyhan syndrome.

  1984cited by this paper
• BENZODIAZEPINE TREATMENT FOR LESCH‐NYHAN SYNDROME?

  1980cited by this paper
• The use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome

  1976cited by this paper
• The Effect of L-5-Hydroxytryptophan on Self-Mutilation in Lesch-Nyhan Disease: A Negative Report

  1976cited by this paper
• Double-blind clinical trial of 5-hydroxytryptophan in a case of Lesch-Nyhan syndrome.

  1976cited by this paper
• Prophylactic Effect of L-5-Hydroxytryptophan on Self-Mutilation in the Lesch-Nyhan Syndrome

  1975cited by this paper
• Adenine and Folic Acid in the Lesch-Nyhan Syndrome

  1973cited by this paper
• Adenine Therapy for Lesch-Nyhan Syndrome

  1971cited by this paper
• THE INFLUENCE OF ADENINE ON THE CLINICAL FEATURES AND PURINE METABOLISM IN THE LESCH‐NYHAN SYNDROME

  1970cited by this paper
• A FAMILIAL DISORDER OF URIC ACID METABOLISM AND CENTRAL NERVOUS SYSTEM FUNCTION.

  1964cited by this paper

• D1 dopamine receptor antagonists as a new therapeutic strategy to treat autistic-like behaviours in lysosomal storage disorders

  2025cites this paper
• Management of neurological symptoms in Lesch-Nyhan disease: a systematic review.

  2024influential citation
• Single-Electrode Deep Brain Stimulation of Bilateral Posterolateral Globus Pallidus Internus in Patients With Medically Resistant Lesch-Nyhan Syndrome

  2023cites this paper
• Chlorpromazine, an Inverse Agonist of D1R-Like, Differentially Targets Voltage-Gated Calcium Channel (CaV) Subtypes in mPFC Neurons

  2023cites this paper
• Concise Synthesis of Chiral Tricyclic Lactams by Tandem Dynamic Kinetic Asymmetric Reductive Amination/Lactamization Using Ammonium Salts.

  2023cites this paper
• Ecopipam: A D1 receptor antagonist for the treatment of Tourette syndrome

  2022cites this paper
• Systematic Review of N-of-1 Studies in Rare Genetic Neurodevelopmental Disorders

  2021cites this paper
• Purine and Pyrimidine Metabolism

  2021cites this paper
• 50 Years Ago in T J P

  2021cites this paper
• 50 Years Ago in TheJournalofPediatrics: Diagnosis of Self-Mutilation and Hyperuricemia.

  2021cites this paper
• Novel treatments for autism spectrum disorder based on genomics and systems biology.

  2021cites this paper
• Neurobiology of Self-Injurious Behavior

  2020cites this paper
• Late diagnosis of Lesch–Nyhan disease complicated with end-stage renal disease and tophi burst: a case report

  2020cites this paper
• Self-injurious behaviour in movement disorders: systematic review

  2020cites this paper
• Scoping review of symptoms in children with rare, progressive, life-threatening disorders

  2019cites this paper
• Current understanding of Lesch-Nyhan disease and potential therapeutic targets

  2019cites this paper
• Chemical synthesis, microbial transformation and biological evaluation of tetrahydroprotoberberines as dopamine D1/D2 receptor ligands.

  2019cites this paper
• Dopamine D1 and D3 receptor modulators restore morphine analgesia and prevent opioid preference in a model of neuropathic pain.

  2019cites this paper
• Management of Pediatric Movement Disorders: Present and Future.

  2018cites this paper
• Morphine responsiveness to thermal pain stimuli is aging-associated and mediated by dopamine D1 and D3 receptor interactions.

  2017cites this paper
• Lesch–Nyhan syndrome and its variants: examining the behavioral and neurocognitive phenotype

  2017cites this paper
• Long-term treatment with dopamine D3 receptor agonists induces a behavioral switch that can be rescued by blocking the dopamine D1 receptor.

  2017cites this paper
• Towards rational drug treatment of Lesch-Nyhan disease.

  2016cites this paper
• Lesch-Nyhan Syndrome: Models, Theories, and Therapies

  2016cites this paper